Pharma

Your Article Summary

See Latest Articles

Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Teva Pharmaceutical Industries, 02/16/09

Teva Pharmaceutical Industries Ltd. and Active Biotech announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis, has received a Fast Track designation from the U.S. Food and Drug Administration. Teva completed enrollment for the first of its two Phase III clinical trials for laquinimod in November 2008 and is currently enrolling RRMS patients globally for the second Phase III study.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

Safety First in Biotech Development
BioPharm, 12/03/09

Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09

Complete Genomics and GATC Biotech Collaborate on Human Genome Sequencing Projects
b3c newswire, 12/02/09

 See all of Biotechnology

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09

Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

 See all of Drug Trials